ACRO Biomedical Co Ltd
Acro Biomedical Co., Ltd. engages in the development and marketing of nutritional products in Indiana and internationally. It is involved in the development and sale of cordyceps related products, a fungus used in traditional Chinese medicine. The company was formerly known as Killer Waves Hawaii, Inc. and changed its name to Acro Biomedical Co., Ltd. in January 2017. Acro Biomedical Co., Ltd. wa… Read more
ACRO Biomedical Co Ltd (ACBM) - Total Liabilities
Latest total liabilities as of September 2025: $436.94K USD
Based on the latest financial reports, ACRO Biomedical Co Ltd (ACBM) has total liabilities worth $436.94K USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
ACRO Biomedical Co Ltd - Total Liabilities Trend (2015–2025)
This chart illustrates how ACRO Biomedical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
ACRO Biomedical Co Ltd Competitors by Total Liabilities
The table below lists competitors of ACRO Biomedical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SITC INTL HLDGS
BE:7S8
|
Germany | €753.24 Million |
|
Koramco Energy Plus Reit Co Ltd
KO:357120
|
Korea | ₩781.19 Billion |
|
Aberdeen Global IF Inc
NYSE MKT:FCO
|
USA | $17.48 Million |
|
AUSTOCK GRP
BE:5A9
|
Germany | €3.44 Billion |
|
SINGTEL 1000
BE:SIT4
|
Germany | €21.23 Billion |
|
ARTPRICE COM (AJP.SG)
STU:AJP
|
Germany | €11.47 Million |
|
Braxia Scientific Corp
PINK:BRAXF
|
USA | $2.70 Million |
|
AMERN VANGUARD CORP
BE:AVJ
|
Germany | €454.23 Million |
Liability Composition Analysis (2015–2025)
This chart breaks down ACRO Biomedical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.01 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 101.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ACRO Biomedical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ACRO Biomedical Co Ltd (2015–2025)
The table below shows the annual total liabilities of ACRO Biomedical Co Ltd from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $326.95K | 0.00% |
| 2024-12-31 | $326.95K | +62.57% |
| 2023-12-31 | $201.12K | 0.00% |
| 2022-12-31 | $201.12K | +71.35% |
| 2021-12-31 | $117.37K | -62.40% |
| 2020-12-31 | $312.19K | +133.17% |
| 2019-12-31 | $133.89K | -44.37% |
| 2018-12-31 | $240.68K | +550.84% |
| 2017-12-31 | $36.98K | +113.43% |
| 2016-12-31 | $17.33K | +2000.12% |
| 2015-12-31 | $825.00 | -- |